Professor Karl J. Hale

The 2010 Japan Society for the Promotion of Science Fellowship Lecture Tour of Japan
Total Synthesis of the Antitumour Natural Products (+)-Kettapeptin and (+)-Azinothricin and A New Formal Synthesis of (+)-Pumiliotoxin B Via O-Directed Alkyne Free Radical Hydrostannation
Eisai Pharmaceutical Company, Tsukuba, Japan, 30 November 2010
Kitasato University, Tokyo, Japan, 30 November 2010
Astellas Pharmaceutical Company, Tokyo, Japan, 29 November 2010
Yokohama National University, Yokohama, Japan, 27 November 2010
Takeda Pharmaceutical Company, Tsukuba, Japan, 26 November 2010
Department of Chemistry, University of Tsukuba, Tsukuba, Japan, 26 November 2010
Kyowa-Hakko Kirin Pharmaceutical Company, Mishima, Japan, 25 November 2010
Ono Pharmaceutical Company, Kyoto, Japan, 24 November 2010
School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan, 24 November 2010
Doshisha Women's College of Liberal Arts, Kyoto, Japan, 22 November 2010
Department of Applied Chemistry, Keio University, Tokyo, Japan, 20 November 2010
School of Chemistry & Life Sciences, Tohoku University, Sendai, Japan, 19 November 2010
University of Tokyo, Tokyo, Japan, 17 November 2010
Tokyo Institute of Technology, Tokyo, 16 November 2010
Daiichi-Sankyo Pharmaceutical Company, Tokyo, Japan, 15 November 2010

Synthetic Strategies for the Construction of Complex Oligosaccharides and Glycosides
Takeda Pharmaceutical Company, Tsukuba, Japan, 26 November 2010

Asymmetric Formal Total Synthesis of the Antitumour Macrolide Bryostatin 7 and Its Use For Analogue Construction
1^st Sino-Ireland Synthetic Chemistry Symposium, University College Dublin, Ireland, 30 July 2010

Total Synthesis of (+)-A83586C, (+)-Kettapeptin and (+)-Azinothricin: Powerful New Inhibitors of β-Catenin/TCF4 and E2F-Mediated Gene Transcription
Journees de Chimie Moleculaire Symposium for 2010, Pierre and Marie Curie University, Paris, France, 27 May 2010
Temple University, Philadelphia, USA 18 March 2010
University of Texas at San Antonio, USA, 21 December 2009
Columbia University, New York, USA, 14 August 2009
AstraZeneca Wilmington, Delaware, USA, 11 August 2009
ACS Symposium ‘A Celebration of Organic Synthesis’ to mark the 65th Birthday of Prof. Amos B. Smith III, Rutgers University, Piscataway, New Jersey, USA, 13 August 2009
RSC 21st International Symposium on Organic Synthesis, St Catherine’s College, Oxford, UK 20 July 2009

Formal Asymmetric Total Synthesis of the Antitumour Macrolide, Bryostatin 7
RSC North Eastern Region Regional Symposium, Durham University, Durham, UK, 15 April 2010
Queen’s University of Belfast, NI, UK (RSC Inaugural Lecture), 16 December 2009

Formal Asymmetric Total Synthesis of Bryostatin 7 and a New Total Synthesis of (+)-Eremantholide A
University of Pennsylvania, Philadelphia, USA 12 August, 2009
Almac, Craigavon, NI, 24 June 2008

Total Synthesis of the Antitumour Natural Products A83586C, Kettapeptin and Azinothricin and Allied Chemical Genomics Studies
Randox Laboratories, Aldergrove, NI, UK, 29 July 2009
RSC Cancer Chemistry Symposium, University of Galway, Ireland, 3 July 2009
University of Nottingham, UK May 2009

Total Synthesis and Chemical Genomics Studies on the Azinothricin/A83586C/Kettapeptin Antitumour Natural Products
The Synthesis of Bioactive Molecules V Symposium, University College Cork, Cork, Ireland, 14 May 2009

Total Synthesis of the Anticancer Natural Products Kettapeptin, Azinothricin and Agelastatin and Allied Chemical Genomics Studies
Department of Chemistry, Colorado State University, Fort Collins, USA, 25 March 2009.

Synthesis of (+)-Kettapeptin and (+)-Azinothricin and Antitumour Studies on Molecules Related to A83586C
Centenary Symposium, School of Chemistry, Queen’s University Belfast, 28 October 2008

Total Synthesis of the Antitumour Agents Kettapeptin and Azinothricin and Allied Chemical Genomics Studies
University of Missouri, St. Louis, USA, 10 April 2008

Total Synthesis and Chemical Genomics Studies on Important Antitumour Natural Products
RSC “Chemistry and Cancer” Meeting, University College Dublin, Ireland, 15 February 2008

Total Synthesis and Chemical Genomics Studies on the Azinothricin and Agelastatin Families of Antitumour Natural Products
QUB Biomedical Sciences Department, Belfast, NI, UK, 22 January 2008

Total Synthesis and Chemical Genomics Studies on Important Antitumour Natural Products
RSC “Chemistry and Cancer” Meeting, University College Dublin, Ireland, 15 February 2008
Trinity College Dublin, Ireland, 8 November 2007

Total Synthesis and Chemical Genomics Studies on the A83586C/Azinothricin Antitumour Agents and (+)-Eremantholide A
RWTH Aachen, Aachen, Germany, 28 November 2007
Liebig-Universität Gießen, Gießen, Germany, 27 November 2007
Max Planck Institute of Molecular Physiology, Dortmund, Germany, 23 November 2007

2007 German Chemical Society Liebig Lectureship Tour of Germany
Total Synthesis and Chemical Genomics Studies on the A83586C/Azinothricin Natural Products and Towards a Biogenetically Modelled Asymmetric Total Synthesis of Halichomycin
BASF AG, Ludwigshafen, Germany, 30 November 2007
Universität Hannover, Hannover, Germany, 29 November 2007
Humboldt-Universität Berlin, Berlin, Germany, 26 November 2007
Universität Stuttgart, Stuttgart, Germany, 22 November 2007
Ludwig-Maximilians-Universität München, Munich, Germany, 21 November 2007
Universität Saarland, Saarbrücken, Germany, 20 November 2007
Universität Freiburg, Freiburg, Germany, 19 November 2007

Total Synthesis and Chemical Genomics Studies on the A83586C/Azinothricin Natural Products
10^th International Conference of the Chemistry of Antibiotics & Other Biocative Compounds at Vanderbilt University, USA, August, 2007

Total Synthesis and Chemical Genomics Studies on the Antitumour Agents Bryostatin 7, (-)-Agelastatin A, and (+)-Eremantholide A
UCB-Celltech, Slough, UK, December 2006

Total Synthesis and Chemical Genomics Studies on Important Antitumour Natural Products
Trinity College Dubllin, Dublin, Ireland, November 2007
German Chemical Society, GDCh Biennial Chemistry Forum, Ulm, Germany, September 2007
12^th Brazilian Meeting on Organic Synthesis, Itapema, Brazil, August 2007
London School of Pharmacy, UK, May 2007
University of Newcastle, UK, May 2007
Eisai London Laboratories, London, UK, November 2006
Schering AG, Berlin, Germany, October 2006
University of Arizona, Tucson, Arizona, USA, September 2006
University of Glasgow, Glasgow, UK, February 2006

Synthetic Studies on the Bryostatin 7 and Halichomycin Antitumor Natural Products, and a New Synthetic Protocol For the O-Directed Free Radical Hydrostannation of Disubstituted Alkynes
University of Virginia, Chalottesville, Virginia, USA, September 2005

Formal Asymmetric Total Synthesis of the Antitumor Macrolide Bryostatin 7, and Some Recent Advances in the O-Directed Free Radical Hydrostannation of Disubstituted Alkynes
F. Hoffmann-La Roche, Basel, Switzerland, October 2005
University of Fribourg, Switzerland, October 2005
Temple University, Philadelphia, USA August 2005
Astra Zeneca, Wilmington, Delaware, USA, August 2005

Total Synthesis and Chemical Genomics Studies on the Marine Antitumour Natural Products Bryostatin 7, (-)-Agelastatin A and Halichomycin
University of Liverpool, Liverpool, UK, January 2005

Towards a Biogenetically-Modelled Total Synthesis of the Marine Antitumour Agent Halichomycin
Amos Smith, 60^th Birthday Symposium, U of Penn., Philadelphia, USA, October 2004

Total Synthesis Studies on the Marine Antitumour Agents (-)-Agelastatin A and Halichomycin
Louis Pasteur University, Strasbourg, France, November 2004
London School of Pharmacy, London, UK, September 2004.

Total Synthesis and Chemical Genomics Studies on the Antitumour and GSK-3 Inhibitory Alkaloid (-)-Agelastatin A
SCI Conference: A Celebration of Organic Chemistry, University of Warwick, September 2004
Johnson & Johnson Pharmaceuticals, Raritan, New Jersey, USA, August 2004
F. Hoffmann La Roche, Nutley, New Jersey, USA, August 2004
RSC Symposium: Cancer Therapeutics in the 21st Century, UMIST, October 2003

Chemical Genomics Meets Natural Product Total Synthesis
University of British Columbia, Canada, April 2004

Enantiospecific Total Synthesis of the Antitumour and Glycogen Synthase Kinase 3-β Inhibiting Alkaloid, (-)-Agelastatin A, and a Powerful New Radical-Based Method for Trisubstituted Olefin Construction
Vertex Pharmaceuticals, Oxford, UK, January 2004
Pfizer, Sandwich, UK, December 2003

Enantiospecific Total Synthesis of the Antitumour and GSK-3β Inhibitory Alkaloid (-)-Agelastatin A
University of Oxford, Oxford, October 2003

Novel Histone Deacetylase Inhibitors, Telomerase Inhibitors and Chromatin Remodelling Agents Based Upon the Antitumour Natural Product FR901228
Kudos Pharmaceuticals, Cambridge, UK, October 2003
Novartis Pharmaceuticals, East Hanover, USA, November 2003

Powerful New TCF4 Inhibitory Drugs That Act on Deregulated E-Cadherin/β-Catenin and Wnt/β-Catenin Signalling Pathways
Novartis Pharma AG, Oncology Taskforce, Basel, Switzerland, October 2003

Powerful New Immunosuppressants That Act by Selectively Inhibiting Histone Deacetylases
Novartis Pharma AG, Transplantation Group, Basel, Switzerland, October 2003

Synthetic and Chemical Biological Investigations on the Bryostatin Family of PKC Modulators
Novartis Respiratory Research Centre, Horsham, UK, September 2003

Synthetic and Biophysical Studies on the Bryostatin Antitumour Macrolides
GlaxoSmithKline, King of Prussia, Philadelphia, USA, March 2003

Total Synthesis Studies on the Bryostatin Antitumour Macrolides
ACS Ernest Guenther Awards Symposium, New Orleans, USA, March 2003

Synthetic and Biological Studies on the A83586C and Bryostatin Families of Antitumour Agents
Bristol-Myers Squibb Symposium, University of Illinois at Chicago, Chicago, USA, March 2003

Total Synthesis and Chemical Biology Studies on the A83586C/GE3/Citropeptin Family of Antitumour Cyclodepsipeptides
Novartis Oncology Taskforce, Basel, Switzerland, September 2002

The Chemistry and Biology of the A83586C/GE3 Family of Antitumour Antibiotics, and Progress Towards a Biogeneticaly Modelled Total Synthesis of the Marine Antitumour Agent Halichomycin
Eisai Research Institute, August 2002
AstraZeneca, Boston, USA, August 2002